Urology

Non-muscle invasive bladder cancer, representing roughly 75% of cases, remains confined to the bladder lining and submucosa, often recurring but rarely advancing.

Patients treated on the entire prostate or surgical bed had better DMFS compared to those treated only on the relapse site.

Results showed that US overestimated bladder volumes compared to CBCT, with an average deviation of 60.75 ml.

Profiling urine tumour DNA at baseline and after 3 months of treatment could identify whether patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer might not benefit from systemic immunotherapy.

These insights are particularly relevant in minimally invasive surgery, where precision and confidence are vital.

The GETSBI study is not only crucial for this specific patient group but also holds broader implications for research in rare, chronic conditions.

Preliminary outcomes indicated that AE may improve haemoglobin levels, possibly counteracting androgen deprivation therapy induced reductions.

The guidelines endorse adjuvant nivolumab for patients with pT3/4 and/or pN+ disease who are unsuitable for, or have declined, cisplatin-based chemotherapy.